TY - JOUR
T1 - Pharmacokinetics of (6S)-leucovorin and 5-methyltetrahydrofolate after 4-hour continuous intravenous infusion followed by repeated oral doses of (6S)-leucovorin in patients with colorectal cancer treated with 5-fluorouracil
AU - Vannozzi, Maria O.
AU - Nobile, Maria T.
AU - Sanguineti, Ornella
AU - Barzacchi, Cristina
AU - Viale, Maurizio
AU - Numico, Gianmauro
AU - Esposito, Mauro
PY - 1996
Y1 - 1996
N2 - As part of a clinical trial of 5-fluorouracil (5-FU) administered as a 24-hour intravenous infusion in patients with colorectal carcinoma, pharmacokinetic studies of (6S)-leucovorin [(6S)-LV] and its major metabolite 5-methyltetrahydrofolate (5-CH3-THF) were performed in 8 patients given a continuous intravenous infusion of(6S)-LV 100 mg/m2 followed by 5 oral doses of (6S)-LV 50 mg. The aim of this study was to assess whether 5 oral doses of (6S)-LV 50 mg administered after intravenous treatment can maintain the plasma concentrations of reduced folates within the range shown to optimise 5-FU cytotoxicity throughout a 24-hour period of 5-FU treatment. The pharmacokinetics of (6S)-LV 50 mg administered orally was investigated in 4 additional patients. The mean (± SD) plasma concentrations of (6S)-LV and 5-CH3-THF after 4-hour infusion of (6S)-LV, before 5-FU treatment, were 14.5 ± 3.1 μmol/L and 4.7 ± 2.8 μmol/L, respectively; at 4 hours postinfusion, before starting repeated oral doses, their concentrations were 1.2 ± 0.5 μmol/L and 3.6 ± 1.4 μmol/L, respectively. At 4 hours after a single oral dose of (6S)-LV 50 mg, the mean plasma concentrations of (6S)-LV and 5-CH3-THF were 0.4 ± 0.2 μmol/L and 2.7 ± 1.0 μmol/L. (6S)-LV was cleared from plasma more slowly after oral [mean residence time (MRT) = 2.1 ± 0.2 hours] than after intravenous treatment (MRT = 1.5 ± 0.5 hours). At the end of 5-FU treatment, after 5 oral doses of (6S)-LV 50 mg, the mean plasma concentrations of total reduced folates [(6S)-LV + 5-CH3-THF] were in the range reported for the synergism with fluoropyrimidines after either intravenous (3.1 ± 0.9 μmol/L) or oral treatment (2.7 ± 0.6 μmol/L). The present study suggests that a regimen combining a 4-hour continuous infusion followed by repeated oral doses of (6S)-LV is able to maintain modulating plasma concentrations of total bioactive folates throughout a 24-hour continuous infusion of 5-FU.
AB - As part of a clinical trial of 5-fluorouracil (5-FU) administered as a 24-hour intravenous infusion in patients with colorectal carcinoma, pharmacokinetic studies of (6S)-leucovorin [(6S)-LV] and its major metabolite 5-methyltetrahydrofolate (5-CH3-THF) were performed in 8 patients given a continuous intravenous infusion of(6S)-LV 100 mg/m2 followed by 5 oral doses of (6S)-LV 50 mg. The aim of this study was to assess whether 5 oral doses of (6S)-LV 50 mg administered after intravenous treatment can maintain the plasma concentrations of reduced folates within the range shown to optimise 5-FU cytotoxicity throughout a 24-hour period of 5-FU treatment. The pharmacokinetics of (6S)-LV 50 mg administered orally was investigated in 4 additional patients. The mean (± SD) plasma concentrations of (6S)-LV and 5-CH3-THF after 4-hour infusion of (6S)-LV, before 5-FU treatment, were 14.5 ± 3.1 μmol/L and 4.7 ± 2.8 μmol/L, respectively; at 4 hours postinfusion, before starting repeated oral doses, their concentrations were 1.2 ± 0.5 μmol/L and 3.6 ± 1.4 μmol/L, respectively. At 4 hours after a single oral dose of (6S)-LV 50 mg, the mean plasma concentrations of (6S)-LV and 5-CH3-THF were 0.4 ± 0.2 μmol/L and 2.7 ± 1.0 μmol/L. (6S)-LV was cleared from plasma more slowly after oral [mean residence time (MRT) = 2.1 ± 0.2 hours] than after intravenous treatment (MRT = 1.5 ± 0.5 hours). At the end of 5-FU treatment, after 5 oral doses of (6S)-LV 50 mg, the mean plasma concentrations of total reduced folates [(6S)-LV + 5-CH3-THF] were in the range reported for the synergism with fluoropyrimidines after either intravenous (3.1 ± 0.9 μmol/L) or oral treatment (2.7 ± 0.6 μmol/L). The present study suggests that a regimen combining a 4-hour continuous infusion followed by repeated oral doses of (6S)-LV is able to maintain modulating plasma concentrations of total bioactive folates throughout a 24-hour continuous infusion of 5-FU.
UR - http://www.scopus.com/inward/record.url?scp=0029775078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029775078&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029775078
VL - 12
SP - 39
EP - 45
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
SN - 1173-2563
IS - 1
ER -